microbio-web-header.jpg

April 18-20, 2018  |  Boston, MA USA

More Information About the 2018 Event is Coming Soon!

Emeran Mayer, World-Renowned Gastroenterologist and Neuroscientist, to Deliver Keynote Address at 4th Annual Translational Microbiome Conference

Leading researcher on mind-body interactions will speak on his work and emerging science on neurobiological aspects of digestive and nervous system interaction regarding health and disease

MINNEAPOLIS, November 16, 2017 – Dr. Emeran Mayer will deliver the keynote address at the 4th Annual Translational Microbiome Conference. Dr Mayer is a pioneer in researching brain-body interactions, focusing especially on brain-gut interactions in relation to health and disease. Besides being a widely recognized expert for functional GI disorders, he is also recognized as one of the leading investigators in the world of chronic visceral pain and of the brain-gut axis. Dr. Mayer’s keynote speech is closed to the public but open to registered conference attendees. The conference, which will be hosted by Arrowhead Publishers April 18-20 at the Boston Marriott Long Wharf, provides insight and collaboration opportunities between scientists at the forefront of microbiome research and pioneering companies investing to apply microbiome-based findings to innovate medical solutions.

“Not only is Dr. Mayer a leader in microbiome research,” said John Waslif, Managing Director of Arrowhead Publishers. “His career of investigative research has uncovered such pivotal findings that entire bodies of work are growing from that rich foundation. We are fortunate to hear firsthand about his newest research in April.”

A prolific research author, Dr. Mayer has published 210 original manuscripts in leading GI and Neuroscience journals, and 95 book chapters and reviews, has co-edited three books, and serves as Associate Editor of Gastroenterology. He is director of the Gail and Gerald Oppenheimer Family Center for Neurobiology of Stress. Having served as president of the Functional Brain Gut group, he is also a regular member of the National Institute of Diabetes and Digestive and Kidney Diseases’ Clinical, Integrative and Molecular Gastroenterology study section. Dr. Mayer is currently engaged in research on sex differences in functional GI disorders, brain-bladder interactions, and brain imaging in IBS.

Just as Dr. Mayer’s findings span several medical specialties, his and other recent discoveries illustrate the many essential roles the human microbiome plays within the human ecosystem, and scientists are discovering specific variables within the microbiome that can profoundly impact a variety of conditions and diseases. To align with these findings and support exploration of translational applications, conference topics are broadly applicable, spanning multiple disease states, including oncology and dermatology, as well as inflammatory, cognitive and digestive disorders. In addition to Dr. Mayer’s keynote, progress from other groundbreaking researchers will be shared in conference sessions, and poster board presentations will offer direct access to discuss recent findings and current studies of key interest to the microbiome discussion.

The Translational Microbiome Conference will focus and build upon the challenges and hurdles that companies working in the microbiome space will have to recognize and navigate in order to successfully commercialize their products. Research in the microbiome represents tremendous potential to provide more effective therapies and supplements, and as investment opportunities are growing in this area, many companies are rapidly pursuing potential translational work. Sharing key learnings in this space can lend greater efficiency to the development and availability of new pharmaceutical offerings, and sessions will offer insight to how innovative companies are meeting challenges head-on to apply recent discoveries to a variety of disease processes.

Additional speakers for the 2018 Translational Microbiome Conference will be announced soon, and further information about the conference can be found at www.microbiomeconference.com.

There are several ways for interested parties to engage with conference speakers and attendees.

Request a conference brochure and register to attend

Submit a proposal for a speaking role
Become an exhibitor
Sponsor a panel session, lunch or refreshment break

Submit a poster session abstract

Contact:   John Waslif, Managing Director

                Arrowhead Publishers

Phone:     866-945-0263 (extension 700)

Email:      This email address is being protected from spambots. You need JavaScript enabled to view it.

Website:  www.arrowheadpublishers.com

Expert Panel Discussions to be Highlight of Agenda at the 3rd Annual Translational Microbiome Conference

Minneapolis, MN – February 15, 2017 – Arrowhead Publishers is pleased to announce that a variety of expert panel discussions have been announced for its upcoming 3rd Annual Translational Microbiome Conference. This event, which will take place April 11-13, 2017 in Boston, MA, will unite presenters and attendees from academia, industry, and the government to provide a multi-stakeholder perspective on the latest trends and developments in the microbiome space. For more information, visit: http://www.microbiomeconference.com.

The CEO of CosmosID Inc. Manoj Dadlani will lead the panel on bioinformatics tools for clinical applications in metagenomics, as well as challenges to overcome in the complex clinical and regulatory environments. Panelists will also discuss the dire need for robust bioinformatics tools that can address the complex clinical and regulatory environments.

Co-founder and CEO of Whole Biome, Dr. Colleen Cultcliffe, will be leading a panel discussion on the microbiome and its growing presence in the media. As new therapeutics are being developed, the microbiome industry must find ways to overcome the hype and unrealistic timelines that can be expected by the general public.

Mohan S. Iyer, CBO at Second Genome, will be moderating the panel on pharma companies working in the microbiome industry. He and the panelists will discuss the latest partnerships between the microbiome industry and pharma, and the deals outlook for 2017.

The “Strategies and Risks for Developing Comprehensive Patent and Licensing Strategies” panel will be led by Greg Sieczkiewicz, Managing Director at MPM Capital. This panel will analyze the various challenges and opportunities that organizations will experience when developing a patent portfolio in the microbiome therapeutics industry. They will also discuss what is necessary from a licensing perspective in order to create a successful pharma-biotech relationship.

Director of Research and Development of Reckitt Benckiser, Joe Rubino, will moderate the panel discussion “Time to Put the Hygiene Hypothesis to Rest?”

JP Benya, Vice President Commercial of Assembly Biosciences will lead the panel discussion on commercial challenges and opportunities in the microbiome-based therapeutics industry. By focusing on critical factors to consider when launching a MBT including regulatory considerations, customer expectations, and messaging implications, this panel will provide expert insight into the future of microbiome-based therapeutics.

Arrowhead Publishers’ 3rd Annual Translational Microbiome Conference will continue to focus and build on the challenges and hurdles that companies working in the microbiome space will have to recognize and navigate in order to successfully commercialize their products. With a broad focus spanning multiple disease states (oncology, dermatology, inflammatory disorders, among others), attendees will have the opportunity to hear the leading companies discuss integral components of successful businesses. For more information, visit: http://www.microbiomeconference.com/brochure.

For more information, please contact:

John Waslif: Managing Director

Arrowhead Publishers

866-945-0263 ext 700

This email address is being protected from spambots. You need JavaScript enabled to view it.

Rachel Donlon: Marketing Associate

Arrowhead Publishers

866-945-0263 ext 701

This email address is being protected from spambots. You need JavaScript enabled to view it.

Metagenomics Expert Rita Colwell to Deliver Keynote Address at Arrowhead’s 3rd Annual Translational Microbiome Conference

January 5, 2017 – Minneapolis, MN – The second keynote presentation at Arrowhead Publishers’ 3rd Annual Translational Microbiome Conference will be given by Dr. Rita Colwell, Distinguished Professor at Johns Hopkins Bloomberg School of Public Health and founder of CosmosID. Her presentation will provide attendees with an overview of the application of metagenomics in improving knowledge of human biology, disease, and the environment. The conference will be taking place April 11-13, 2017 in Boston, MA. For more information, visit: http://www.microbiomeconference.com.

In an era of climate change, high-throughput sequencing and high-resolution bioinformatics are becoming increasingly powerful in microbiome studies, as well as the clinical management of infectious disease and environment. Dr. Colwell will provide several examples of using metagenomics in a clinical setting, including diarrheal disease, waterborne infections, and wastewater reuse.

Founded in 2008 by Dr. Colwell, CosmosID strives to make the world a healthier and safer place by delivering high-resolution bioinformatics for personalized monitoring of environmental bio threat agents in an accurate and cost-effective manner. For more information, visit: http://www.cosmosid.com.

Arrowhead Publishers’ 3rd Annual Translational Microbiome Conference will continue to focus and build on the challenges and hurdles that companies working in the microbiome space will have to recognize and navigate in order to successfully commercialize their products. With a broad focus spanning multiple disease states (oncology, dermatology, inflammatory disorders, among others), attendees will have the opportunity to hear the leading companies discuss integral components of successful businesses. For more information, visit: http://www.microbiomeconference.com/brochure.

For more information, please contact:

John Waslif: Managing Director

Arrowhead Publishers

866-945-0263 ext 700

This email address is being protected from spambots. You need JavaScript enabled to view it.

Rachel Donlon: Marketing Associate

Arrowhead Publishers

866-945-0263 ext 701

This email address is being protected from spambots. You need JavaScript enabled to view it.

Thought Leader in Microbiome Research Jack Gilbert to Present at Arrowhead Publishers’ 3rd Annual Translational Microbiome Conference

2 December 2016 – Minneapolis, MN – Jack Gilbert, the faculty director of The Microbiome Center and professor at the University of Chicago, has just been announced as the keynote speaker at Arrowhead Publishers’ 3rd Annual Translational Microbiome Conference. This conference will once again unite top companies in the microbiome space working to successfully commercialize microbiome-based diagnostics and therapeutics. This conference will be taking place April 11-13, 2017 in Boston, MA. For more information on the conference, visit: http://www.microbiomeconference.com.

As the human microbiome is quickly demonstrating huge roles in the human ecosystem, scientists are discovering that changes in the microbiome have a huge impact on a variety of conditions and diseases. Dr. Gilbert will discuss the latest evidence of these mechanisms of interaction, and how we have started to disturb the delicate balance of immune-microbe equilibrium, thus impacting the development and function of our immune systems. By applying new strategies to identify how the microbial ecosystem correlates with diseases and treatment efficacy through Microbiome-Wide Association Studies (MWAS), microbiome studies are providing a new framework for facilitating patient care.

With an increasing awareness that many of our modern diseases are “lifestyle” related and more than 50% of current medications are ineffective for the people taking them, research in the microbiome presents a potential opportunity to provide more effective treatments, cures, therapies and supplements. Reflective of this trend is the fact that investment opportunities are growing in this area and many companies are rapidly moving towards potential translational work. 

Arrowhead Publishers’ 3rd Annual Translational Microbiome Conference will continue to focus and build on the challenges and hurdles that companies working in the microbiome space will have to recognize and navigate in order to successfully commercialize their products. With a broad focus spanning multiple disease states (oncology, dermatology, inflammatory disorders, among others), attendees will have the opportunity to hear the leading companies discuss integral components of successful businesses. For more information, visit: http://www.microbiomeconference.com/brochure.

For more information, please contact:

John Waslif: Managing Director

Arrowhead Publishers

866-945-0263 ext 700

This email address is being protected from spambots. You need JavaScript enabled to view it.

Rachel Donlon: Marketing Associate

Arrowhead Publishers

866-945-0263 ext 701

This email address is being protected from spambots. You need JavaScript enabled to view it.

Arrowhead Announces the Preliminary Speaker Faculty for 3rd Annual Translational Microbiome Conference

November 16 2016 – Minneapolis, MN – Arrowhead Publishers has announced the preliminary speaking faculty for the 3rd Annual Translational Microbiome Conference. This conference, taking place April 11-13, 2017 in Boston, MA, will once again bring together the top companies in the microbiome space working to successfully commercialize microbiome-based diagnostics, therapeutics, adjunct therapies and direct-to-consumer services and products.

This year’s conference will continue to focus and build on the challenges and hurdles that companies working in the microbiome industry will have to recognize and navigate in order to successfully commercialize their products. For more information on the conference, visit: http://www.microbiomeconference.com.

Speakers Include:

  • James Arbogast, Ph.D., VP of Hygiene Sciences and Public Health Advancements, GOJO Industries
  • JP Benya, VP Commercial, Assembly Biosciences
  • Carrie Brodmerkel, Ph.D., Senior Director, Systems Pharmacology & Biomarkers, Janssen R&D
  • Martha Carlin, Chief Executive Revolutionary, The BioCollective
  • Rodolphe Clerval, Chief Business Officer, Enterome
  • Rita Colwell, Ph.D., Distinguished Professor, Univ. of Maryland at College Park, Johns Hopkins Univ. Bloomberg School of Public Health, President, CosmosID, Inc., Senior Advisor, Canon U.S. Life Sciences, Inc.
  • Colleen Cutcliffe, Ph.D., Co-Founder and CEO, Whole Biome
  • Manoj Dadlani, Chief Executive Officer, CosmosID
  • Xavier Duportet, Chief Executive Officer, Eligo Biosciences
  • Jack Gilbert, Ph.D., Faculty Director, The Microbiome Center, Professor, Department of Surgery, The University of Chicago, Senior Scientist (Adjunct), The Marine Biological Laboratory, Group Leader in Microbial Ecology, Argonne National Laboratory
  • Wa’el Hashad, Executive VP and CCO, Seres Therapeutics
  • Mohan Iyer, Chief Business Officer, Second Genome
  • Lee Jones, Founder, President and CEO, Rebiotix
  • Colleen Kelly, MD, FACG, Gastroenterologist, Center for Women’s Gastrointestinal Medicine, Women’s Medicine Collaborative
  • Arpita Maiti, Ph.D., Director, External R&D Innnovation, Inflammation & Immunology, Pfizer
  • KT Moortgat, Ph.D., Chief Executive Officer, Osel
  • Bernat Olle, Ph.D., Chief Executive Officer, Vedanta Biosciences
  • Jack Oswald, Co-Founder, CTO and CEO, IsoThrive
  • Jackie Papkoff, Ph.D., SVP Research, Evelo Biosciences
  • Greg Sieczkiewicz, JD, Ph.D., Managing Director, Chief IP Counsel, MPM Capital
  • Larry Weiss, MD, Chief Medical Officer, AOBiome
  • James White, Ph.D., Founder, Resphera Biosciences

For more information, visit: http://www.microbiomeconference.com/brochure.

This year brings several exciting additions to the conference, designed to offer attendees insights that they can implement in their own organizations. First, this year’s conference will feature two parallel tracks on the second day, closely focused on the nutrition and consumer industries within the microbiome space.

In addition, the conference will offer hands-on, intensive pre-conference workshops to help attendees understand real-world issues and give them the tools to better address how these issues impact their businesses.

For more information, please contact:

John Waslif: Managing Director
Arrowhead Publishers
866-945-0263 ext 700
This email address is being protected from spambots. You need JavaScript enabled to view it.
 
Rachel Donlon: Marketing Associate
Arrowhead Publishers
866-945-0263 ext 701
This email address is being protected from spambots. You need JavaScript enabled to view it.